ArticleProtein engineering, design & selection : PEDS2026
Incorporation of azide groups into an engineered Fn3 scaffold protein for site-specific, bioorthogonal conjugation.
Article in Protein engineering, design & selection : PEDS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Protein bioconjugates have a wide range of applications, including for targeted drug delivery and in vivo diagnostics. Expanding the chemistry available to link protein to cargo remains a critical consideration for the development of novel bioconjugates for unmet needs. Currently, most FDA-approved protein bioconjugates are based on the antibody structure, which constrains the available conjugation chemistries and applications. Alternative scaffold proteins have potential as targeting molecules that advance the synthetic possibilities. Here, we report two methods of high-yield incorporation of azide-containing groups into an Fn3 domain protein scaffold to enable click chemistry conjugation. One approach incorporates noncanonical amino acid azidohomoalanine during recombinant protein expression, and the other method develops a linker system using a unique thiol residue in the Fn3 structure. These synthetic approaches enabled orthogonal, dual labeling. The resulting conjugates retain functionality in receptor binding assays, validating these methods for diverse applications in engineering scaffold proteins for bioconjugate applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.